Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Characterization of a pESI-like plasmid and analysis of multidrug-resistant Salmonella enterica Infantis isolates in England and Wales
Microbial Genomics  (IF5.237),  Pub Date : 2021-10-14, DOI: 10.1099/mgen.0.000658
Winnie W. Y. Lee, Jennifer Mattock, David R. Greig, Gemma C. Langridge, David Baker, Samuel Bloomfield, Alison E. Mather, John R. Wain, Andrew M. Edwards, Hassan Hartman, Timothy J. Dallman, Marie A. Chattaway and Satheesh Nair

  Salmonella enterica   serovar Infantis is the fifth most common   Salmonella   serovar isolated in England and Wales. Epidemiological, genotyping and antimicrobial-resistance data for   S  .   enterica   Infantis isolates were used to analyse English and Welsh demographics over a 5 year period. Travel cases associated with   S  .   enterica   Infantis were mainly from Asia, followed by cases from Europe and North America. Since 2000, increasing numbers of   S  .   enterica   Infantis had multidrug resistance determinants harboured on a large plasmid termed ‘plasmid of emerging   S  .   enterica   Infantis’ (pESI). Between 2013 and 2018, 42   S  .   enterica   Infantis isolates were isolated from humans and food that harboured resistance determinants to multiple antimicrobial classes present on a pESI-like plasmid, including extended-spectrum β-lactamases (ESBLs; bla CTX-M-65). Nanopore sequencing of an ESBL-producing human   S  .   enterica   Infantis isolate indicated the presence of two regions on an IncFIB pESI-like plasmid harbouring multiple resistance genes. Phylogenetic analysis of the English and Welsh   S  .   enterica   Infantis population indicated that the majority of multidrug-resistant isolates harbouring the pESI-like plasmid belonged to a single clade maintained within the population. The bla CTX-M-65 ESBL isolates first isolated in 2013 comprise a lineage within this clade, which was mainly associated with South America. Our data, therefore, show the emergence of a stable resistant clone that has been in circulation for some time in the human population in England and Wales, highlighting the necessity of monitoring resistance in this serovar.